Replication-selective oncolytic viruses in the treatment of cancer
- PMID: 15472714
- DOI: 10.1038/sj.cgt.7700771
Replication-selective oncolytic viruses in the treatment of cancer
Erratum in
- Cancer Gene Ther. 2005 Apr;12(4):438
Abstract
In the search for novel strategies, oncolytic virotherapy has recently emerged as a viable approach to specifically kill tumor cells. Unlike conventional gene therapy, it uses replication competent viruses that are able to spread through tumor tissue by virtue of viral replication and concomitant cell lysis. Recent advances in molecular biology have allowed the design of several genetically modified viruses, such as adenovirus and herpes simplex virus that specifically replicate in, and kill tumor cells. On the other hand, viruses with intrinsic oncolytic capacity are also being evaluated for therapeutic purposes. In this review, an overview is given of the general mechanisms and genetic modifications by which these viruses achieve tumor cell-specific replication and antitumor efficacy. However, although generally the oncolytic efficacy of these approaches has been demonstrated in preclinical studies the therapeutic efficacy in clinical trails is still not optimal. Therefore, strategies are evaluated that could further enhance the oncolytic potential of conditionally replicating viruses. In this respect, the use of tumor-selective viruses in conjunction with other standard therapies seems most promising. However, still several hurdles regarding clinical limitations and safety issues should be overcome before this mode of therapy can become of clinical relevance.
Similar articles
-
Advances in oncolytic viral therapy.Curr Opin Investig Drugs. 2006 Jun;7(6):549-59. Curr Opin Investig Drugs. 2006. PMID: 16784026 Review.
-
Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer.Oncogene. 2000 Dec 27;19(56):6660-9. doi: 10.1038/sj.onc.1204094. Oncogene. 2000. PMID: 11426652 Review.
-
Oncolytic viruses for the treatment of cancer: current strategies and clinical trials.Drug Discov Today. 2004 Sep 1;9(17):759-68. doi: 10.1016/S1359-6446(04)03221-0. Drug Discov Today. 2004. PMID: 15450242 Review.
-
Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy.J Exp Ther Oncol. 2004 Apr;4(1):37-57. J Exp Ther Oncol. 2004. PMID: 15255291 Review.
-
Oncolytic adenoviruses - selective retargeting to tumor cells.Oncogene. 2005 Nov 21;24(52):7775-91. doi: 10.1038/sj.onc.1209044. Oncogene. 2005. PMID: 16299537 Review.
Cited by
-
Oncolytic viruses in the treatment of cancer: a review of current strategies.Pathol Oncol Res. 2012 Oct;18(4):771-81. doi: 10.1007/s12253-012-9548-2. Epub 2012 Jun 20. Pathol Oncol Res. 2012. PMID: 22714538 Review.
-
Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.Surgery. 2012 Sep;152(3):441-8. doi: 10.1016/j.surg.2012.05.040. Epub 2012 Jul 31. Surgery. 2012. PMID: 22853858 Free PMC article.
-
Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.Cancer Gene Ther. 2011 Mar;18(3):153-66. doi: 10.1038/cgt.2010.52. Epub 2010 Sep 24. Cancer Gene Ther. 2011. PMID: 20865021 Free PMC article.
-
Exploring the contribution of distal P4 promoter elements to the oncoselectivity of Minute Virus of Mice.Virology. 2007 Apr 25;361(1):174-84. doi: 10.1016/j.virol.2006.11.006. Epub 2006 Dec 18. Virology. 2007. PMID: 17175002 Free PMC article.
-
Oncolytic Virotherapy versus Cancer Stem Cells: A Review of Approaches and Mechanisms.Cancers (Basel). 2018 Apr 19;10(4):124. doi: 10.3390/cancers10040124. Cancers (Basel). 2018. PMID: 29671772 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical